KIDSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
ORTHOPEDIATRICS CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$22.03+0.08 (+0.36%)
Close on Oct 19, 2026
- Market cap
- $529.79M
- P/E (TTM)
- –
- Dividend yield
- –
ORTHOPEDIATRICS CORP revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trauma and deformity | $166.30M | $145.13M | $106.78M | $85.06M | $65.83M | $47.68M | $49.37M | $39.70M | $32.80M | $26.84M | 70.4% | +14.6% |
| Scoliosis | $66.05M | $55.15M | $37.93M | $33.43M | $28.05M | $20.74M | $21.49M | $16.66M | $11.59M | $9.35M | 27.9% | +19.8% |
| Sports medicine/other | $4.00M | $4.45M | $4.02M | – | – | – | – | – | – | – | 1.7% | -10.1% |
| Sports medicine/other | – | $4.45M | $4.02M | $3.81M | $4.17M | $2.66M | $1.70M | $1.20M | $1.23M | $1.11M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $186.40M | $161.16M | $111.01M | $92.42M | $77.78M | $62.97M | $55.06M | $43.46M | $34.91M | $28.84M | 78.9% | +15.7% |
| International | $49.95M | $43.56M | $37.72M | $29.87M | $20.27M | $8.11M | $17.50M | $14.10M | $10.71M | $8.46M | 21.1% | +14.6% |
From the segment and revenue-disaggregation notes of Orthopediatrics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.